• Explore /
  • Poster
  • / BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.

BRCA-1 promotor methylation as predictor of benefit from adjuvant CMF in triple-negative breast cancer not responsive to taxane-based neoadjuvant chemotherapy.

Abstract Poster

Authors

null

Rupert Bartsch

Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

Rupert Bartsch , Mathilde Födermayr , Miriam Sebesta , Margaretha Rudas , Anna Sophie Berghoff , Regina Promberger , Matthias Preusser , Peter Christian Dubsky , Florian Fitzal , Michael Gnant , Ansgar Weltermann , Christoph Zielinski , Guenther G. Steger , Otto Zach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Breast Cancer Symposium

Session Type

Poster Discussion Session

Session Title

General Session VIII: Poster Discussion B

Track

Risk Assessment, Prevention, Detection, and Screening,Systemic Therapy,Local/Regional Therapy,Survivorship and Health Policy

Sub Track

Triple-Negative

Citation

J Clin Oncol 31, 2013 (suppl 26; abstr 148)

DOI

10.1200/jco.2013.31.26_suppl.148

Abstract #

148

Poster Bd #

B6

Abstract Disclosures

Similar Posters

First Author: Cheng Wang

First Author: Priyanka Sharma

First Author: Kenji Tamura

First Author: Joyce O'Shaughnessy